Revenue segments as reported by the company.

Subscription services

Professional services and other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and admin

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veeva Systems

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Veeva Systems reports robust Q1 earnings, eyes growth opportunities

Veeva Systems delivered strong financial performance in Q1 2023, driven by robust execution and competitive wins. The company's focus on innovation, AI capabilities, and the transition to Vault CRM presents significant growth opportunities. However, challenges in the funding environment and customer migrations pose potential hurdles.

Veeva exceeds Q2 expectations, anticipates growth in clinical and data business

Veeva's Q2 performance exceeded expectations, leading to an increase in full-year guidance. The company's strengths lie in strong clinical activity, customer wins, and a focus on product excellence. However, challenges include migration costs, competitive landscape considerations, and marketing spend scrutiny. Veeva sees opportunities in M&A, minimal impact from R&D trends, and expansion of Veeva Link.

Veeva Systems surpasses Q3 expectations, eyes clinical data opportunity

Veeva Systems delivered a strong Q3 performance, with solid revenue and operating income. While facing challenges in billings and macroeconomic uncertainties, the company remains confident in its revenue target for fiscal year '25. The commitment from major enterprises and the potential in clinical data present significant opportunities for future growth.

Veeva Systems reports strong Q4 performance and forecasts $2.8B revenue

Veeva Systems showcases strong performance and strategic planning with revenue growth expectations of at least 15% in fiscal '24 and '25.
Positive feedback on product transitions and development, along with specialized sales teams, highlights market acceptance and innovation.
Challenges include short-term revenue impacts from timing-related issues and macro environment effects on customer spending.
Opportunities lie in revenue growth forecasts, product innovation, and market differentiation through new offerings and strategic deals.

Veeva Systems reports robust Q1 revenue growth and strategic focus

Veeva Systems' Q1 performance reflects strong revenue growth and a focus on customer-centric innovation. The company faces challenges in project scrutiny and competition but has opportunities in new product monetization and segment expansion.

Veeva Systems excels in Q2, eyes disciplined growth and innovation

Veeva Systems showcased robust financial performance, exceeding revenue and operating income targets, with a strong focus on customer success and product excellence.
While facing challenges such as migration costs and regulatory impacts, Veeva is well-positioned to leverage opportunities in disciplined M&A and product innovation.
The company's strategic growth initiatives, including Veeva Link expansion and CRM platform enhancements, aim to drive continued success and value for customers.

Veeva Systems posts solid Q3 results, eyes growth opportunities

Veeva Systems delivered a strong Q3 performance with solid revenue and operating income, showcasing financial stability and growth potential.
Despite challenges like trimmed billings and deal delays, Veeva remains confident in its fiscal year '25 revenue target, emphasizing strategic focus and operational efficiency.
The company's strengths in innovative products, strong partnerships, and global support ecosystem position it well for future growth and market leadership.
Opportunities in customer migration, AI integration, and market demand present avenues for Veeva to drive revenue growth and enhance its competitive positioning in the industry.

Veeva Systems excels in Q4 earnings, poised for strategic growth

Veeva Systems delivered strong financial performance in Q4 2024, showcasing revenue growth, operating income efficiency, and strategic product advancements.
The company's focus on innovation, customer success, and disciplined financial guidance positions it well for future growth and market leadership.
While facing challenges related to market uncertainties and operational considerations, Veeva remains resilient and poised to capitalize on opportunities for expansion and differentiation.
Overall, Veeva's Q4 earnings call highlights a balanced approach to growth, operational excellence, and strategic decision-making in a dynamic business environment.

Veeva Systems beats Q1 guidance, lowers full-year outlook amid challenges

Veeva Systems had a strong start to the year, exceeding Q1 guidance but lowering full-year revenue outlook due to macro challenges.
The company's performance in margin, client adoption, and innovation remains robust, with a focus on stability and predictability amidst industry challenges.
Challenges include AI disruption impacting plans, lower revenue guidance, and delays in funding benefits due to global conflicts and interest rate sensitivity.
Opportunities lie in new client bases, EDC deals progress, and the potential growth of Vault Basics and Link products in the market.

Veeva Systems excels in Q2, eyes strategic growth opportunities

Veeva Systems delivered a strong Q2 performance with revenue of $676 million and non-GAAP operating income of $280 million, driven by product expansions and customer wins.
The company's strengths lie in its comprehensive clinical suite, customer comfort with CRM solutions, and the importance of professional services for customer success.
Challenges include short-term billing growth constraints and the need for continuous product excellence, while opportunities exist in data architecture enhancement and upcoming Investor Day insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity

These businesses dominate their rapidly growing niche markets.

A Bull Market Is Coming: 2 Exceptional Growth Stocks to Buy Now and Hold Forever

The growth stock is rallying so far this year, but how long will that last?

Is Veeva Systems Stock a Buy Now?

Digital marketing innovators cut time to market by more than half and drive more meaningful engagements across the biopharma industry with Veeva Vault PromoMats PLEASANTON, Calif. , Feb. 16, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that biopharmas are leveraging Veeva Vault PromoMats for modular content to accelerate medical, legal, and regulatory (MLR) reviews and drive more impactful engagement across channels and regions.

Modular Content Powers Omnichannel Engagement at Speed and Scale

SAN FRANCISCO & LONDON--(BUSINESS WIRE)--David Bennett brings 30 years of C-level software industry leadership experience to drive hyper growth as Red Sift CRO

Former Veeva Executive Joins Red Sift as Chief Revenue Officer

Duolingo

Even a volatile market can be a great time to scoop up wonderful companies.

Buying These 2 Under-the-Radar Stocks for 2023 Could Be a Smart Move

Salesforce

Zscaler

These stocks are shrewd buys ahead of the next market recovery.

Got $2,000? Here Are 3 Smart Stocks to Buy Now

PLEASANTON, Calif. , Jan. 31, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2023, after market close on March 1, 2023.

Veeva to Release Fiscal 2023 Fourth Quarter and Full Year Results on March 1, 2023

VEEV's move away from Salesforce creates opportunity. The company has been one of the best-run SaaS names.

Veeva Moving Away From Salesforce Creates An Opportunity

In the Nintai Investments 2022 Annual Review, fund manager and GuruFocus contributor Thomas Macpherson wrote, “During the bear market in 2022, we used nearly every dollar of our cash reserves to add to existing holdings. Many of these were trading at compelling prices.

Veeva: A Value Stock that's Growing Rapidly

Veeva Systems is a cloud-based software solution provider for the pharmaceutical and life sciences industries. Veeva is valued at over $20 billion and is considered a top player in the industry, providing its services to hundreds of pharmaceutical and life sciences companies worldwide.

Veeva Systems: A Leading Provider Of Cloud-Based Solutions For The Pharmaceutical Industry

New Oriental Education & Technology Group

Masimo

Monolithic Power Systems

Skyworks Solutions

T. Rowe Price Group

Tyler Technologies

Nintai Investments: 2022 Annual Review

When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

Veeva Systems (VEEV) Crossed Above the 50-Day Moving Average: What That Means for Investors

Align Technology

Alnylam Pharmaceuticals

Baxter

BeiGene

Bristol-Myers

Royalty Pharma

Teleflex

Universal Health Services

Walgreens

Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.

5 Best and Worst Performing Health Care Stocks in December 2022

Veeva Systems' (VEEV) slew of product launches raises optimism about the stock.

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

"There's no other competitor that does this as well as Veeva."

Veeva Systems Stock Is a Healthcare Gem

Airbnb

These companies aren't doing nearly as badly as their recent stock market performances might suggest.

2 Growth Stocks Down 35% or More to Buy and Hold in 2023 and Beyond

Autodesk

C3.ai

Digital Turbine

Asana

Alteryx

Bill.com

Datadog

Dynatrace Inc

Elastic N.V

Robinhood

MongoDB

Matterport

nCino, Inc.

Okta

UiPath

Paycom Software

Palantir Technologies

Pubmatic

SentinelOne

Snowflake

Trade Desk

Unity Software

Stock based compensation or SBC for short has been a focus of many lately given the egregious numbers posted quarter-after-quarter in financial results. The point of all this investor anxiety towards SBC is the resulting devastating dilution that may occur if the billions in options are actually exercised.

Stock Based Compensation: The Dilution Potential Of The Worst Offenders

Investors aren't the only market players getting more bearish on the healthcare tech specialist.

Why Veeva Systems Stock Flopped While the Market Popped Today

Vault Quality Suite to connect quality processes, documents, and training on a single platform for improved efficiency and collaboration PLEASANTON, Calif. , Jan. 11, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Adare Pharma Solutions, a contract development and manufacturing organization (CDMO) with expertise in oral dosage forms, selected Veeva Vault Quality Suite to harmonize quality systems across the organization.

Global CDMO Adare Pharma Solutions Harmonizing Quality with Veeva Vault Quality Suite

Non-competes stifle the U.S. economy, innovation, and employee rights PLEASANTON, Calif. , Jan. 10, 2023 /PRNewswire/ -- Consistent with its long-standing work to abolish non-compete agreements, Veeva Systems (NYSE: VEEV) today announced its support for the proposed Federal Trade Commission (FTC) rule to ban employee non-competes.

Veeva Statement in Support of Proposed FTC Rule to Ban Non-Competes

PLEASANTON, Calif. , Jan. 9, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Peter Gassner, founder and CEO, will present at the 41st Annual J.P.

Veeva to Present at the 41st Annual J.P. Morgan Healthcare Conference

DigitalOcean Holdings

Shopify

The stock market is packed with more opportunities than ever for first-time investors.

How to Invest $15,000 Today If You Had to Start From Scratch

Investors were disappointed by Veeva's growth and profit forecasts.

Why Did Veeva Systems Stock Fall 15% in December?

Incyte

Inspire Medical Systems Inc

Madrigal Pharmaceuticals

Schrodinger 

Verona Pharma

Viatris

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.

Why These 7 Healthcare Stocks Could Soar in 2023

News for Veeva Systems Stock (VEEV)